New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Ovid Therapeutics Inc. is changing its finance leadership while keeping continuity. The company and Jeffrey Rona, its Chief Business and Financial Officer and principal financial and accounting officer, mutually agreed to his transition from these roles effective July 6, 2026. The board appointed Charles Carter, previously Senior Vice President of Finance and Financial Planning, as Chief Financial Officer, principal financial officer, principal accounting officer and secretary from the same date. The company states that Rona’s departure is not due to any disagreement over accounting, controls, operations or policies.
Carter will receive a $460,000 annual base salary, a target bonus equal to 35% of salary, and 50,000 restricted stock units vesting in two equal annual installments starting July 6, 2027, plus an additional cash bonus opportunity of $75,000. Rona’s separation agreement provides 12 months of base salary, a prorated 2026 bonus, up to 12 months of COBRA benefits, and post-termination non-solicitation covenants. He will serve as a consultant through December 31, 2027, earning a one-time cash retainer and hourly consulting fees, with his existing equity awards continuing to vest during the consulting period.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
New CFO base salary: $460,000 per year
New CFO bonus target: 35% of base salary
RSU grant to new CFO: 50,000 shares
+4 more
7 metrics
New CFO base salary
$460,000 per year
Annual base salary for Charles Carter as CFO
New CFO bonus target
35% of base salary
Target annual cash bonus percentage for Charles Carter
RSU grant to new CFO
50,000 shares
Restricted stock units vesting in two equal annual installments from July 6, 2027
Additional cash bonus opportunity
$75,000
Potential extra cash bonus for Charles Carter based on objectives and goals
Rona salary continuation
12 months of base salary
Severance period following July 6, 2026 separation date
COBRA benefits duration
Up to 12 months
Health coverage period for Jeffrey Rona after separation
Consulting period end
December 31, 2027
End date of Jeffrey Rona’s consulting agreement
Key Terms
restricted stock unit, COBRA, non-solicitation, Separation Agreement, +2 more
6 terms
restricted stock unit financial
"Mr. Carter was granted a restricted stock unit award with respect to 50,000 shares"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
COBRA financial
"COBRA benefits for a period of up to 12 months from the Separation Date"
COBRA is a U.S. federal law that lets employees and their dependents temporarily keep employer-sponsored health insurance after job loss, reduction in hours, or other qualifying events by paying the premiums themselves. Investors should care because offering COBRA can affect a company’s cash flow, administrative costs and legal disclosures when workforce changes occur—similar to a former club member paying to keep their membership active after leaving the club.
non-solicitation regulatory
"post-termination restrictive covenants, including non-solicitation restrictions that will continue"
A non-solicitation clause is a contractual promise that one party will not actively try to lure away another party’s employees, customers, or suppliers. For investors, it signals protection of a company’s workforce and client base after a deal or partnership—reducing the risk that key staff or revenue sources will be poached and therefore helping preserve the business’s value, predictability, and post-transaction earnings. Think of it as an agreement not to knock on a neighbor’s door to take their business or team.
Separation Agreement regulatory
"the Company entered into a separation agreement and general release with Mr. Rona"
A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.
Consulting Agreement regulatory
"the Company has also entered into a consulting agreement with Mr. Rona"
principal financial officer financial
"Chief Business and Financial Officer, principal financial officer, principal accounting officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
FAQ
What leadership change did Ovid Therapeutics (OVID) announce?
Ovid Therapeutics announced that Jeffrey Rona will transition out of his roles as Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary. Charles Carter, previously Senior Vice President of Finance and Financial Planning, will become Chief Financial Officer and assume those principal officer roles effective July 6, 2026.
Why is Ovid Therapeutics’ outgoing CFO Jeffrey Rona leaving his roles?
Ovid Therapeutics states that Jeffrey Rona’s transition from his executive roles was mutually agreed and is not due to any disagreement regarding accounting practices, financial statements, internal controls, operations, policies or practices. He will continue supporting the company under a consulting agreement extending through December 31, 2027.
What is the compensation package for new Ovid Therapeutics CFO Charles Carter?
Charles Carter will receive a $460,000 annual base salary, an annual cash bonus target equal to 35% of salary, and 50,000 restricted stock units vesting in two equal annual installments beginning July 6, 2027. He also has an additional cash bonus opportunity of $75,000 tied to corporate and individual performance.
What severance benefits will outgoing Ovid executive Jeffrey Rona receive?
Jeffrey Rona is eligible for 12 months of his base salary paid in monthly installments, a prorated 2026 annual bonus paid in a lump sum, and up to 12 months of COBRA health benefits. His separation agreement also includes post-termination non-solicitation covenants lasting one year after his separation date.
How long will Jeffrey Rona continue working with Ovid Therapeutics?
Jeffrey Rona will remain involved under a consulting agreement through December 31, 2027, providing advisory services. He will receive a one-time cash retainer plus hourly consulting fees, and his existing equity awards will continue to vest during the consulting period, supporting continuity during the finance leadership transition.
Does Charles Carter have prior public-company CFO experience before joining Ovid (OVID)?
Yes. Charles Carter previously served as Chief Financial Officer and Corporate Secretary of CERo Therapeutics Holdings, Inc. from February 2024 to September 2024, where he prepared that company for a complex de-SPAC transaction and public launch, and also held CFO roles at iCAD, Inc. and GI Dynamics, Inc.